Amgen Inc
AMGN327.380USD
+2.960+0.91%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
176.29BMarket Cap
25.14P/E TTM
More Details of Amgen Inc Company
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Amgen Inc Info
Ticker SymbolAMGN
Company nameAmgen Inc
IPO dateJun 17, 1983
CEOBradway (Robert A)
Number of employees28000
Security typeOrdinary Share
Fiscal year-endJun 17
AddressOne Amgen Center Drive
CityTHOUSAND OAKS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91320-1799
Phone18054471000
Websitehttps://www.amgen.com/
Ticker SymbolAMGN
IPO dateJun 17, 1983
CEOBradway (Robert A)
Company Executives of Amgen Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+1.52%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+3.06%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
34.82K
-16.50%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+4.94%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+6.57%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
7.57K
+11.97%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
7.35K
+12.36%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
6.66K
-14.35%
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
6.04K
--
Dr. Michael V. Drake, M.D.
Dr. Michael V. Drake, M.D.
Independent Director
Independent Director
4.89K
+4.69%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+1.52%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+3.06%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
34.82K
-16.50%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+4.94%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+6.57%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
7.57K
+11.97%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Other products
1.69B
18.41%
Prolia
1.12B
12.22%
Repatha
696.00M
7.58%
Otezla
618.00M
6.73%
Enbrel
604.00M
6.58%
Other
4.45B
48.47%
By RegionUSD
Name
Revenue
Proportion
US
5.93B
64.59%
ROW
2.32B
25.32%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Other products
1.69B
18.41%
Prolia
1.12B
12.22%
Repatha
696.00M
7.58%
Otezla
618.00M
6.73%
Enbrel
604.00M
6.58%
Other
4.45B
48.47%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.96%
State Street Investment Management (US)
5.44%
BlackRock Institutional Trust Company, N.A.
5.30%
Capital International Investors
3.56%
Capital World Investors
3.49%
Other
72.25%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.96%
State Street Investment Management (US)
5.44%
BlackRock Institutional Trust Company, N.A.
5.30%
Capital International Investors
3.56%
Capital World Investors
3.49%
Other
72.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.48%
Investment Advisor/Hedge Fund
19.12%
Research Firm
4.87%
Pension Fund
2.19%
Bank and Trust
1.99%
Sovereign Wealth Fund
1.18%
Insurance Company
0.63%
Hedge Fund
0.42%
Individual Investor
0.17%
Other
15.96%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
4407
451.47M
85.20%
+63.91K
2025Q3
4486
451.61M
85.29%
-1.24M
2025Q2
4487
452.85M
84.91%
+2.52M
2025Q1
4500
450.78M
83.12%
+3.88M
2024Q4
4470
440.57M
82.15%
+6.55M
2024Q3
4290
435.41M
82.39%
-1.01M
2024Q2
4260
436.06M
82.34%
+1.04M
2024Q1
4169
435.45M
81.98%
-3.93M
2023Q4
4130
433.32M
81.14%
+5.55M
2023Q3
3960
428.67M
80.98%
-560.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
53.86M
10%
+393.81K
+0.74%
Aug 29, 2025
State Street Investment Management (US)
29.36M
5.45%
+177.03K
+0.61%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
28.83M
5.36%
+326.43K
+1.15%
Jun 30, 2025
Capital International Investors
18.91M
3.51%
+3.78M
+24.95%
Jun 30, 2025
Capital World Investors
16.86M
3.13%
+157.99K
+0.95%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
12.89M
2.4%
+687.74K
+5.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
13.02M
2.42%
+291.27K
+2.29%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
11.01M
2.04%
-38.88K
-0.35%
Aug 31, 2025
PRIMECAP Management Company
10.63M
1.97%
-1.76M
-14.18%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
8.82M
1.64%
+91.95K
+1.05%
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Dec 1
Updated: Mon, Dec 1
Name
Proportion
VanEck Biotech ETF
12.81%
FT Vest DJIA Dogs 10 Target Income ETF
12.23%
ProShares Ultra Nasdaq Biotechnology
8.42%
Invesco Nasdaq Biotechnology ETF
8.35%
Simplify Health Care ETF
7.93%
iShares Biotechnology ETF
7.08%
Invesco Dow Jones Industrial Average Dividend ETF
6.24%
Amplify Weight Loss Drug & Treatment ETF
5.87%
Invesco Pharmaceuticals ETF
5.05%
Invesco Biotechnology & Genome ETF
5.01%
View more
VanEck Biotech ETF
Proportion12.81%
FT Vest DJIA Dogs 10 Target Income ETF
Proportion12.23%
ProShares Ultra Nasdaq Biotechnology
Proportion8.42%
Invesco Nasdaq Biotechnology ETF
Proportion8.35%
Simplify Health Care ETF
Proportion7.93%
iShares Biotechnology ETF
Proportion7.08%
Invesco Dow Jones Industrial Average Dividend ETF
Proportion6.24%
Amplify Weight Loss Drug & Treatment ETF
Proportion5.87%
Invesco Pharmaceuticals ETF
Proportion5.05%
Invesco Biotechnology & Genome ETF
Proportion5.01%
Dividend
A total of
21.35B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Oct 31, 2025
AMGN.NB Final Cash Dividend of gross USD 2.38 paid on Dec 12, 2025 going ex on Nov 21, 2025
Nov 21, 2025
Dec 12, 2025
Nov 21, 2025
Aug 01, 2025
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Sep 12, 2025 going ex on Aug 22, 2025
Aug 22, 2025
Sep 12, 2025
Aug 22, 2025
Mar 04, 2025
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Jun 06, 2025 going ex on May 16, 2025
May 16, 2025
Jun 06, 2025
May 16, 2025
Dec 10, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 07, 2025
Feb 14, 2025
Oct 25, 2024
AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024
Nov 18, 2024
Dec 09, 2024
Nov 18, 2024
Aug 02, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 06, 2024
Aug 16, 2024
Mar 06, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024
May 17, 2024
Jun 07, 2024
May 16, 2024
Dec 12, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024
Feb 16, 2024
Mar 07, 2024
Feb 15, 2024
Oct 24, 2023
AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023
Nov 17, 2023
Dec 08, 2023
Nov 16, 2023
Aug 01, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 08, 2023
Aug 17, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Amgen Inc?
The top five shareholders of Amgen Inc are:
The Vanguard Group, Inc. holds 53.86M shares, accounting for 10.00% of the total shares.
State Street Investment Management (US) holds 29.36M shares, accounting for 5.45% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 28.83M shares, accounting for 5.36% of the total shares.
Capital International Investors holds 18.91M shares, accounting for 3.51% of the total shares.
Capital World Investors holds 16.86M shares, accounting for 3.13% of the total shares.
The Vanguard Group, Inc. holds 53.86M shares, accounting for 10.00% of the total shares.
State Street Investment Management (US) holds 29.36M shares, accounting for 5.45% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 28.83M shares, accounting for 5.36% of the total shares.
Capital International Investors holds 18.91M shares, accounting for 3.51% of the total shares.
Capital World Investors holds 16.86M shares, accounting for 3.13% of the total shares.
What are the top three shareholder types of Amgen Inc?
The top three shareholder types of Amgen Inc are:
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Amgen Inc (AMGN)?
As of 2025Q4, 4407 institutions hold shares of Amgen Inc, with a combined market value of approximately 451.47M, accounting for 85.20% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.09%.
What is the biggest source of revenue for Amgen Inc?
In FY2025Q2, the Other products business generated the highest revenue for Amgen Inc, amounting to 1.69B and accounting for 18.41% of total revenue.
